Journal of Medical Molecular Biology ›› 2022, Vol. 19 ›› Issue (5): 421-425.doi: 10.3870/j.issn.1672-8009.2022.05.012

Previous Articles     Next Articles

Research Progress of mTOR in Diabetic Angiopathy 

  

  1. 1 Department of Endocrinology, the Ninth Clinical Medical College of Shanxi Medical University, Taiyuan, 030009, China 2Department of Endocrinology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, China  3 Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China  4 Department of Graduate School, Shanxi Medical University, Taiyuan, 030001, China
  • Online:2022-09-30 Published:2023-01-13

Abstract: Diabetic angiopathy is the main cause of disability and death in diabetes. However, strategies for the prevention and treatment of diabetic angiopathy have not achieved ideal results. Mechanistic target of rapamycin kinase ( mTOR) is a serine / threonine kinase presented in eukaryotes and plays an important role in various biological processes. A large number of studies have found that mTOR could participate in the occurrence and progress of diabetic angiopathy by regulating cell proliferation, apoptosis, autophagy, oxidative stress and inflammatory responses. This article reviews the effect and related mechanisms of mTOR on diabetic atherosclerosis, diabetic nephropathy and diabetic retinopathy, and provides a new insight for the prevention and treatment of diabetic angiopathy. 

Key words: mechanistic target of rapamycin kinase, diabetic angiopathy, diabetic atherosclerosis, diabetic retinopathy, diabetic nephropathy 

CLC Number: